The effect of sirolimus on prostate-specific antigen (PSA) levels in male renal transplant recipients without prostate cancer

American Journal of Transplantation

Volumn 8, Issue 12, 2008, Pages 2668-2673

  Chamie, K ^a   Ghosh, P M ^a,b   Koppie, T M ^a,b   Romero, V ^a   Troppmann, C ^a   DeVere White, R W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

Gender; Kidney transplantation; Posttransplant cancer; Posttransplant malignancies; Posttransplant monitoring; Prevention; Prostate cancer; Recipient age; Sirolimus; Tacrolimus; Tumor

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; RAPAMYCIN; TACROLIMUS;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CONTROLLED STUDY; DRUG EFFECT; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER;

CASE-CONTROL STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MASS SCREENING; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SIROLIMUS; TACROLIMUS; TRANSPLANTATION;

EID: 55949122985     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02430.x     Document Type: Article

References (39)

1. Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic: I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot 1975 28 : 721 726.
2. Eng CP, Sehgal SN, Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J Antibiot 1984 37 : 1231 1237.
3. Martel RR, Klicius J, Galet S. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol 1977 55 : 48 51.
4. Morris RE, Meiser BM. Identification of a new pharmacologic action for an old compound. Med Sci Res 1989 17 : 609 610.
5. Kahan BD, Podbielski J, Napoli K, Katz SM, Meier-Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998 66 : 1040 1046.
6. Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007 67 : 369 391.
7. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005 80 : 883 889.
8. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006 17 : 581 589.
9. Sharef S, Jac J, Khan M, Amato R. Rapamycin for androgen-independent prostate cancer (AIPC). J Clin Oncol 2006 ASCO Annual meeting Proceedings Part I. Vol 24, No. 18S : 14584.
10. Cinar B, De Benedetti A, Freeman MR. Post-transcriptional regulation of the androgen receptor by Mammalian target of sirolimus. Cancer Res 2005 65 : 2547 2553.
11. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of sirolimus inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005 65 : 2825 2831.
12. Leichtman AB, Cohen D, Keith D et al. Kidney and pancreas transplantation in the United States, 1997-2006: The HRSA Breakthrough Collaboratives and the 58 DSA Challenge. Am J Transplant 2008 8 : 946 957.
13. Barry M. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001 344 : 1373 1377.
14. Kessler M, Jay N, Molle R, Guillemin F. Excess risk of cancer in renal transplant patients. Transpl Int 2006 19 : 908 914.
15. Ries L, Melbert D, Krapcho M et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD : National Cancer Institute, 2007.
16. Huyghe E, Zairi A, Nohra J, Kamar N, Plante P, Rostaing L. Gonadal impact of target of sirolimus inhibitors (sirolimus and everolimus) in male patients: An overview. Transpl Int 2007 20 : 305 311.
17. Cecka JM. The OPTN/UNOS renal transplant registry. In : Cecka JM, Terasaki PI, eds. Clinical transplants, 2005. Los Angeles, CA : UCLA Immunogenetics Center, 2006 : 1 16.
18. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004 4 : 905 913.
19. Cormier L, Lechevallier E, Barrou B et al. Diagnosis and treatment of prostate cancers in renal-transplant recipients. Transplantation 2003 75 : 237 239.
20. Vajdic CM, McDonald SP, McCredie MRE et al. Cancer incidence before and after kidney transplantation. JAMA 2006 296 : 2823 2831.
21. Kleinclauss F, Gigante M, Neuzillet Y et al. Prostate cancer in renal transplant recipients. Nephrol Dial Transplant 2008 23 : 2374 2380.
22. Thompson I, Pauler DK, Goodman PJ et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004 350 : 2239 2246.
23. Ha R, Jindal RM, Milgrom MM, Leapman SB, Filo RS, Pescovitz MD. Prostate-specific antigen values and their clinical significance in renal transplant recipients. South Med J 1998 91 : 847 850.
24. Morton JJ, Howe SF, Lowell JA, Stratta RJ, Taylor RJ. Influence of end-stage renal disease and renal transplantation on serum prostate-specific antigen. Br J Urol 1995 75 : 498 501.
25. Oberbauer R, Banyai S, Schmidt A, Kornek G, Scheithauer W, Mayer G. Serum tumor markers after renal transplantation. Transplantation 1996 62 : 1506 1509.
26. Kamali K, Zargar MA. Effects of renal transplantation on serum-free and total PSA levels. Transplant Proc 2007 39 : 1027 1028.
27. Bruun L, Ekberg H, Bjork T, Lilja H, Hoglund P, Christensson A. Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation. J Urol 2004 171 : 1432 1435.
28. Marks AR. Cellular functions of immunophilins. Physiol Rev 1996 76 : 631 649.
29. Lee CH, Inoki K, Guan KL. mTOR pathway as a target in tissue hypertrophy. Annu Rev Pharmacol Toxicol 2007 47 : 443 467.
30. Kaper F, Dornhoefer N, Giaccia AJ. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of sirolimus activity and increased translation under hypoxic conditions. Cancer Res 2006 66 : 1561 1569.
31. Culig Z, Klocker H, Bartsch G, Steiner H, Hobisch A. Androgen receptors in prostate cancer. J Urol 2003 170 : 1363 1369.
32. Fritsche L, Budde K, Dragun D, Einecke G, Diekmann F, Neumayer HH. Testosterone concentrations and sirolimus in male renal transplant patients. Am J Transplant 2004 4 : 130 131.
33. Kaczmarek I, Groetzner J, Adamidis I, Landwehr P, Mueller M, Vogeser M. Sirolimus impairs gonadal function in heart transplant recipients. Am J Transplant 2004 4 : 1084 1088.
34. Tondolo V, Citterio F, Panocchia N, Nanni G, Castagneto M. Sirolimus impairs improvement of the gonadal function after renal transplantation. Am J Transplant 2005 5 : 197.
35. Tondolo V, Citterio F, Panocchia N et al. Gonadal function and immunosuppressive therapy after renal transplantation. Transplant Proc 2005 37 : 1915 1917.
36. Klein EA, Platz EA, Thompson IM. Epidemiology, etiology, and prevention of prostate cancer. In : Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, eds. Campbell-Walsh Urology, 9th ed., Vol. 3. Philadelphia : Saunders Elsevier, 2007 : 2854 2873.
37. Shabsigh R, Crawford ED, Nehra A, Slawin KM. Testosterone therapy in hypogonadal men and potentential prostate cancer risk: A systematic review. Int J Impot Res 2008 published online: 17 July 2008 (doi :).
38. Guay AT, Perez JB, Fitaihi WA, Vereb M. Testosterone treatment in hypogonadal men: Prostate-specific antigen level and risk of prostate cancer. Endocr Pract 2000 6 : 132 138.
39. Wang C, Swerdloff RS, Iranmanesh A et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000 85 : 2839 2853.